Ling Deng
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 10%
- Circular RNAs in diseases
- RNA modifications and cancer
- Advanced biosensing and bioanalysis techniques
- RNA Interference and Gene Delivery
- Extracellular vesicles in disease
Papers in
-
- Circular RNAs in diseases 4
- RNA modifications and cancer 4
- Cancer-related gene regulation 2
-
- Cancer-related molecular mechanisms research 6
- MicroRNA in disease regulation 5
- Cancer Genomics and Diagnostics 3
- Co-authors
- Jian‐Yong Shao (9 shared papers)Yi-Xin Zeng (3 shared papers)Ma-Yan Huang (3 shared papers)Qiong Shao (5 shared papers)Qiu-Liang Wu (1 shared paper)Li‐Xu Yan (1 shared paper)Zhihua Li (1 shared paper)Jianjiang Fu (1 shared paper)
In The Last Decade
Ling Deng
43 papers receiving 1.7k citations
Ling Deng's Hit Papers
Peers
Comparison fields: 5 of 110
- Cancer Research 862
- Molecular Biology 928
- Oncology 243
- Hepatology 48
- Immunology 96
Countries citing papers authored by Ling Deng
This map shows the geographic impact of Ling Deng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ling Deng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ling Deng more than expected).
Fields of papers citing papers by Ling Deng
This network shows the impact of papers produced by Ling Deng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ling Deng. The network helps show where Ling Deng may publish in the future.
Co-authors
The 25 scholars most cited alongside Ling Deng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 47 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis Hit paper breakdown → | 2008 | 958 |
| 2 | 2021 | 157 | |
| 3 | 2006 | 52 | |
| 4 | 2023 | 43 | |
| 5 | 2020 | 41 | |
| 6 | 2009 | 34 | |
| 7 | 2019 | 33 | |
| 8 | 2014 | 28 | |
| 9 | Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. | 2014 | 26 |
| 10 | 2010 | 25 | |
| 11 | 2014 | 23 | |
| 12 | 2020 | 20 | |
| 13 | 2019 | 19 | |
| 14 | 2008 | 18 | |
| 15 | 2023 | 15 | |
| 16 | Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study. | 2018 | 15 |
| 17 | 2014 | 15 | |
| 18 | 2015 | 14 | |
| 19 | 2021 | 14 | |
| 20 | 2010 | 13 |
About Ling Deng
Ling Deng is a scholar working on Molecular Biology, Cancer Research, Oncology, Epidemiology and Pathology and Forensic Medicine, having authored 47 papers that have together received 1.7k indexed citations. Recurring topics across this work include Burkholderia infections and melioidosis (7 papers), Cancer-related molecular mechanisms research (6 papers), MicroRNA in disease regulation (5 papers), Circular RNAs in diseases (4 papers), RNA modifications and cancer (4 papers), Cancer Genomics and Diagnostics (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Cancer-related gene regulation (2 papers). The work is most often cited by research in Cancer Research (862 citations), Molecular Biology (928 citations), Oncology (243 citations), Hepatology (48 citations) and Immunology (96 citations). Ling Deng has collaborated with scholars based in China, Sweden and Hong Kong. Frequent co-authors include Jian‐Yong Shao, Yi-Xin Zeng, Ma-Yan Huang, Qiong Shao, Qiu-Liang Wu, Li‐Xu Yan, Zhihua Li, Jianjiang Fu, Xiaorui Su and Juan Peng. Their work appears in journals such as Molecular Carcinogenesis, Chinese Journal of Cancer, Cancer Biomarkers, Cancer Research and Treatment and Disease Markers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.